RE:October Presentation ... informationI like the new presentation well put together (compare with lasts versions):
[url=https://https://www.profoundmedical.com/wp-content/uploads/2017/10/Profound-Corporate-OCT-27.pdf][/url]
They need 110 patients (I don't think it specifically says they have all 110 but the last slide says they expect full enrollment by year end and have already treated 62 patients per slide 12). I assume they have fairly good certainty that they will have all 110 as of October end (when they updated the slides) as there are only 2 months left to year end. I assume they will be able to start giving preliminary results in 2018 which will surely be a catalyst to the stock as it will be an indication of phase II/FDA acceptance and US launch.Also agree that they are likely to leverage Sonalleve locations for TULSA and vice versa - that's all part of the strategy to have the same sales force but 2 potential products to offer.